甲状腺激素类似物的展望
综上所述，针对STRM的发展历程，目前开发的制剂情况见表60-2，虽然将STRMs作为长期治疗血脂异常或代谢性疾病，将是困难的，而且可能是不明智的，但这类配体仍显示出预期的有益效果。因此，在需要重点调节TH信号传导途径的情况下，该配体类似物的用途即可体现。比如STRMs将可能是最有效的短期治疗病态肥胖患者的药物。基于临床前动物研究，预测GC-1肝外效应能诱导人类的脂肪燃烧，并且体重减轻显著，所需的治疗持续时间应当足够短，以避免有害的副作用。研究者已经能够安全地控制啮齿动物的GC-1依赖性体重减轻时间长达60d，并已在几个不同的肥胖小鼠模型使用GC-1，可有效地使体重正常化。在ob/ob小鼠高脂饮食诱导肥胖模型研究中，予以GC-1应用3～4周，可使总体脂肪减少达20%，而同一时期未处理的对照组小鼠脂肪却有5%的增加[49]。针对无法通过其他方法减重的患者，在密切监测其体温和其他有害作用的情况下，予以这样的干预或许也是一个选择。
参考文献
[1] Golden S H, Robinson K A, Saldanha I, et al.Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review[J].J Clin Endocrinol Metab, 2009,94: 1853-1878.
[2] Biondi B.Thyroid and obesity: an intriguing relationship[J].J Clin Endocrinol Metab, 2010,95: 3614-3617.
[3] Braverman L E, Cooper D S.Werner & Ingbar’s The Thyroid: A Fundamental and Clinical Text[M].10th ed.Lippincott, Williams & Wilkins, 2012.
[4] Lee P, Zhao J T, Swarbrick M M, et al.High prevalence of brown adipose tissue in adult humans[J].J Clin Endocrinol Metab, 2011,96: 2450-2455.
[5] Silva J E.The thermogenic effect of thyroid hormone and its clinical implications[J].Annals of internal medicine,2003,139: 205-313.
[6] Crunkhorn S, Patti M E.Links between thyroid hormone action, oxidative metabolism, and diabetes risk? [J]Thyroid, 2008,18: 227-237.
[7] Mullur R, Liu Y Y, Brent G A.Thyroid hormone regulation of metabolism[J].Physiological reviews, 2014,94: 355-382.
[8] Klieverik L P, Sauerwein H P, Ackermans M T, et al.Effects of thyrotoxicosis and selective hepatic autonomic denervation on hepatic glucose metabolism in rats[J].American journal of physiology Endocrinology and metabolism, 2008,294: E513-E520.
[9] Aguayo-Mazzucato C, Zavacki A M, Marinelarena A, et al.Thyroid hormone promotes postnatal rat pancreatic betacell development and glucose-responsive insulin secretion through MAFA[J].Diabetes, 2013,62: 1569-1580.
[10] Furuya F, Shimura H, Yamashita S, et al.Liganded thyroid hormone receptor-alpha enhances proliferation of pancreatic beta-cells[J].The Journal of biological chemistry, 2010,285: 24477-24486.
[11] Verga Falzacappa C, Mangialardo C, Madaro L, et al.Thyroid hormone T3 counteracts STZ induced diabetes in mouse[J].PloS one, 2011,6: e19839.
[12] Marsili A, Aguayo-Mazzucato C, Chen T, et al.Mice with a targeted deletion of the type 2 deiodinase are insulin resistant and susceptible to diet induced obesity[J].PloS one, 2011,6: e20832.
[13] 陈家伦.临床内分泌学[M].上海：上海科学技术出版社，2011.
[14] Lopez D, Abisambra Socarras J F, Bedi M, et al.Activation of the hepatic LDL receptor promoter by thyroid hormone[J].Biochimica et biophysica acta,2007,1771: 1216-1225.
[15] Klein I, Danzi S.Thyroid disease and the heart[J].Circulation, 2007,116: 1725-1735.
[16] Goldstein J L, DeBose-Boyd R A, Brown M S.Protein sensors for membrane sterols[J].Cell, 2006,124: 35-46.
[17] Goldberg I J, Huang L S, Huggins L A, et al.Thyroid hormone reduces cholesterol via a non-LDL receptormediated pathway[J].Endocrinology, 2012,153: 5143-5149.
[18] Tamehiro N, Shigemoto-Mogami Y, Kakeya T, et al.Sterol regulatory element-binding protein-2- and liver X receptor-driven dual promoter regulation of hepatic ABC transporter A1 gene expression: mechanism underlying the unique response to cellular cholesterol status[J].The Journal of biological chemistry, 2007,282: 21090-21099.
[19] Chiang J Y.Bile acids: regulation of synthesis[J].Journal of lipid research, 2009,50: 1955-1966.
[20] Liu Y Y, Brent G A.Thyroid hormone crosstalk with nuclear receptor signaling in metabolic regulation[J].Trends in endocrinology and metabolism: TEM, 2010,21:166-173.
[21] Hashimoto K, Cohen R N, Yamada M, et al.Cross-talk between thyroid hormone receptor and liver X receptor regulatory pathways is revealed in a thyroid hormone resistance mouse model[J].The Journal of biological chemistry, 2006,281: 295-302.
[22] Talukdar S, Bhatnagar S, Dridi S, et al.Chenodeoxycholic acid suppresses the activation of acetyl-coenzyme A carboxylase-alpha gene transcription by the liver X receptor agonist T0-901317[J].Journal of lipid research,2007,48: 2647-2663.
[23] Knight B L, Hebbachi A, Hauton D, et al.A role for PPARalpha in the control of SREBP activity and lipid synthesis in the liver[J].The Biochemical Journal,2005,389: 413-421.
[24] Singh R, Kaushik S, Wang Y, et al.Autophagy regulates lipid metabolism[J].Nature, 2009,458: 1131-1135.(https://www.daowen.com)
[25] Yang L, Li P, Fu S, et al.Defective hepatic autophagy in obesity promotes ER stress and causes insulin resistance[J].Cell metabolism, 2010,11: 467-478.
[26] Chung GE, Kim D, Kim W, et al.Non-alcoholic fatty liver disease across the spectrum of hypothyroidism[J].Journal of hepatology, 2012,57: 150-156.
[27] Pihlajamaki J, Boes T, Kim E Y, et al.Thyroid hormonerelated regulation of gene expression in human fatty liver[J].J Clin Endocrinol Metab, 2009,94: 3521-3529.
[28] Cable E E, Finn P D, Stebbins J W, et al.Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist[J].Hepatology (Baltimore, Md), 2009,49: 407-417.
[29] Kharitonenkov A, Shiyanova T L, Koester A, et al.FGF21 as a novel metabolic regulator[J].The Journal of clinical investigation, 2005,115: 1627-1635.
[30] Adams A C, Astapova I, Fisher F M, et al.Thyroid hormone regulates hepatic expression of fibroblast growth factor 21 in a PPARalpha-dependent manner[J].The Journal of biological chemistry, 2010,285: 14078-14082.
[31] Asvold B O, Bjoro T, Vatten L J.Association of serum TSH with high body mass differs between smokers and never-smokers[J].J Clin Endocrinol Metab, 2009,94:5023-5027.
[32] 胡颖，时立新，孙雪明，等.血清促甲状腺激素与代谢综合征及其组分的相关性[J].中华内分泌代谢杂志， 2013，29： 560-562.
[33] Reinehr T.Obesity and thyroid function[J].Mol Cell Endocrinol, 2010,316: 165-171.
[34] Knudsen N, Laurberg P, Rasmussen L B, et al.Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population[J].J Clin Endocrinol Metab, 2005,90: 4019-4024.
[35] Fox C S, Pencina M J, D’Agostino R B, et al.Relations of thyroid function to body weight: cross-sectional and longitudinal observations in a community-based sample[J].Arch Intern Med, 2008,168: 587-592.
[36] Alevizaki M, Saltiki K, Voidonikola P, et al.Free thyroxine is an independent predictor of subcutaneous fat in euthyroid individuals[J].Eur J Endocrinol, 2009,161:459-465.
[37] Santini F, Galli G, Maffei M, et al.Acute exogenous TSH administration stimulates leptin secretion in vivo[J].Eur J Endocrinol, 2010,163: 63-67.
[38] Radetti G, Kleon W, Buzi F, et al.Thyroid function and structure are affected in childhood obesity[J].J Clin Endocrinol Metab, 2008,93: 4749-4754.
[39] Kok P, Roelfsema F, Langendonk J G, et al.High circulating thyrotropin levels in obese women are reduced after body weight loss induced by caloric restriction[J].J Clin Endocrinol Metab, 2005,90: 4659-4663.
[40] Marzullo P, Minocci A, Tagliaferri M A, et al.Investigations of thyroid hormones and antibodies in obesity: leptin levels are associated with thyroid autoimmunity independent of bioanthropometric,hormonal, and weight-related determinants[J].J Clin Endocrinol Metab, 2010,95: 3965-3972.
[41] Baxter J D, Webb P.Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes[J].Nat Rev Drug Discov, 2009,8: 308-320.
[42] Ribeiro M O, Bianco S D, Kaneshige M, et al.Expression of uncoupling protein 1 in mouse brown adipose tissue is thyroid hormone receptor-beta isoform specific and required for adaptive thermogenesis[J].Endocrinology,2010,151: 432-440.
[43] Grover G J, Mellstrom K, Malm J.Development of the thyroid hormone receptor beta-subtype agonist KB-141:a strategy for body weight reduction and lipid lowering with minimal cardiac side effects[J].Cardiovasc Drug Rev, 2005,23: 133-148.
[44] Berkenstam A, Kristensen J, Mellstrom K, et al.The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans[J].Proc Natl Acad Sci U S A, 2008,105: 663-667.
[45] Ocasio C A, Scanlan T S.Characterization of thyroid hormone receptor alpha (TRalpha)-specific analogs with varying inner- and outer-ring substituents[J].Bioorg Med Chem, 2008,16: 762-770.
[46] Grijota-Martinez C, Samarut E, Scanlan T S, et al.In vivo activity of the thyroid hormone receptor beta- and alphaselective agonists GC-24 and CO23 on rat liver, heart,and brain[J].Endocrinology, 2011,152: 1136-1142.
[47] Malm J, Farnegardh M, Grover G J, et al.Thyroid hormone antagonists: potential medical applications and structure activity relationships[J].Curr Med Chem,2009,16: 3258-3266.
[48] Erion M D, Cable E E, Ito B R, et al.Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index[J].Proc Natl Acad Sci U S A, 2007,104: 15490-15495.
[49] Meruvu S, Ayers S D, Winnier G, et al.Thyroid hormone analogues: where do we stand in 2013? [J].Thyroid,2013,23: 1333-1344.